Clinical Trials Logo

Lung Diseases, Interstitial clinical trials

View clinical trials related to Lung Diseases, Interstitial.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06447831 Recruiting - Clinical trials for Interstitial Lung Disease

Assessing Functional Capacity in Directly and Remotely Monitored Home-based Settings: A Protocol for a Multinational Validation Study in Individuals With Chronic Respiratory Diseases

6MST
Start date: February 2, 2024
Phase:
Study type: Observational

The goal of this validation study is to provide further evidence of the metrological properties of the 6-minute stepper test in individuals with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The main questions it aims to answer are: 1. Is the 6-minute stepper test valid when compared to the 6-minute walk test and a maximal cardiopulmonary cycling test? 2. Does the 6-minute stepper test give the same results when conducted through direct (i.e., therapist in person) and remote (i.e., videoconferencing) monitoring? 3. Is the 6-minute stepper test safe when conducted at the home of the individual with direct (i.e., therapist in person) or remote (i.e., videoconferencing) monitoring? Participants will: - Conduct the 6-minute stepper test (several trials on separate days) - Conduct the 6-minute walk test (1 trial on 1 day) - Conduct a maximal cardiopulmonary test on a cycle ergometer (1 trial on 1 day) - Participate in a semi-structured interview to provide their feedback with regards to the 6-minute stepper test

NCT ID: NCT06440746 Recruiting - Clinical trials for Lung Diseases, Interstitial

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Start date: August 23, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).

NCT ID: NCT06397677 Recruiting - Clinical trials for Rheumatoid Arthritis

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

MOUNTAIN
Start date: January 22, 2024
Phase:
Study type: Observational [Patient Registry]

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

NCT ID: NCT06317831 Recruiting - Clinical trials for Interstitial Lung Diseases

LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease

SUNSET
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

This study aims to i) To characterize the functional status and explore the determinants of functional status decline of people with IlD ii)To determine the measurement properties of functional status instruments in people with Interstitial lung diseases (ILD) iii) To identify the impact of ILD and the participants' perspectives on functional status through interviews iv) Explore the progression of functional status progression in people with ILD and v) Develop a multidimensional index, incorporating functional status parameters, to predict mortality in people with ILD. Patients with ILD will be recruited via the pulmonology services at hospitals, namely from Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), Centro Hospitalar do Baixo Vouga (CHBV) and Centro Hospitalar de Entre o Douro e Vouga (CHEDV). Sociodemographic, clinical characteristics (i.e., smoking habits, vital signs and symptoms), anthropometric (i.e., height and weight to compute body mass index) and general clinical data (i.e., medication, oxygen therapy, non-invasive ventilation, acute exacerbations, hospitalizations and number of hospital admissions in the last month and year, length of stay), as well as prior and follow-up spirometric measurements and arterial blood gas will be collected from clinical records for patients' characterization. Mortality and rehospitalizations will be explored during the study period. Peripheral muscle strength, functional status, daily physical activity, self-reported symptoms, functional status, impact of the disease and health-related quality of life. Qualitative data from interviews. The assessments will be conducted at 6 time points: baseline and 1 week after for instrument validation, followed by assessments every 6 months for 2 years. It is expected that: i) Functional status limitations can be comprehensively identified and measured in individuals with ILD. ii) Some measures are valid and reliable indicators of functional status in individuals with ILD. iii) Different profiles of functional status progression will be identified in individuals with ILD, including stable, slow, and fast decline. iv) A multidimensional index incorporating functional status will improve the accuracy of predicting mortality and outperform the predictive ability of the current GAP Index.

NCT ID: NCT06247397 Recruiting - Clinical trials for Interstitial Lung Disease

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy

HILOT
Start date: June 10, 2024
Phase: N/A
Study type: Interventional

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

NCT ID: NCT06203249 Recruiting - Microbiome Clinical Trials

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Start date: January 20, 2024
Phase:
Study type: Observational

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

NCT ID: NCT06195072 Recruiting - Scleroderma Clinical Trials

Platform Clinical Study for Conquering Scleroderma

CONQUEST
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

NCT ID: NCT06184893 Recruiting - Clinical trials for Rheumatoid Arthritis-Associated Interstitial Lung Disease

Rheumatoid Arthritis-associated Interstitial Lung Disease Definition

RAID
Start date: November 20, 2023
Phase:
Study type: Observational

This is a prospective multicenter study in southern Belgium to determine the prevalence and incidence of interstitial lung disease in patients with rheumatoid arthritis (RA).

NCT ID: NCT06143540 Recruiting - Clinical trials for Interstitial Lung Disease

Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease

Start date: August 16, 2023
Phase:
Study type: Observational

The goal of this observational study is to examine clinical utility of 18F-FAPI-RGD PET/CT imaging in evaluating connective tissue disease-associated interstitial lung disease. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

NCT ID: NCT06141603 Recruiting - Clinical trials for Interstitial Lung Disease

Comparison of Upper and Lower Limb Maximal Exercise Capacities and Muscle Oxygenation in Patients With ILD

Start date: November 25, 2023
Phase:
Study type: Observational

Interstitial lung diseases (ILD) are a complex group of diseases that cause significant morbidity and mortality, develop diffuse lung parenchyma and alveolar inflammation, as well as interstitial fibrosis, which refers to more than 200 diseases. Due to restrictive type ventilation disorder and impaired pulmonary gas exchange, pulmonary function has deteriorated in these patients and progressive shortness of breath, fatigue, cough and exercise intolerance are usually observed, which also affects the quality of life.